ADAM9 and hepatocellular carcinoma: The mean value of pre-treatment plasma ADAM9 mRNA levels in the HCC patients was significantly higher than that in the healthy controls (3.001 ± 0.279 vs. 1.00 ± 0.005, p < 0.05) (Figure 1).